Egypt Osteoporosis Drug Market Growing Trade Among Emerging Economies Opening New Opportunities (2023-2028)

The Egypt Osteoporosis Drug Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Egypt Osteoporosis Drug market. This report explores all the key factors affecting the growth of the global Egypt Osteoporosis Drug market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141597/

Egypts Osteoporosis drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The International Osteoporosis Foundation reported that osteoporosis is a serious disease in the Middle East. It causes the bones to weaken, and they may break easily, become brittle or even develop cancer and infections.

Theprevalenceof osteoporosis is relatively high amongst theEgyptianpopulation and is associated with a wide range of risk factors and medical conditions. Reports show that 53.9% of postmenopausal women have osteopenia while 28.4% have osteoporosis. 21.9% of males aged 20-89 have osteoporosis. Among the primary concerns for the disease treatment market is low awareness among the population. Egyptian Guidelines for the Diagnosis and Management of Osteoporosis have been developed to optimize the use of the existing tools available for the early diagnosis of osteoporosis and to help general practitioners as well as specialists in screening persons with or without risk factors to avoid the occurrence of fractures, especially the first fracture.

Market Drivers

The prevalence of osteoporosis in Egypt has been rated at 28.4% in women and 21.9% in men, whereas 53.9% of women and 26% of men had osteopenia. In rural areas of Upper Egypt, the prevalence of osteoporosis in postmenopausal women was even higher reaching up to 47.8%.

Such high prevalence highlights the magnitude of the problem in terms of public health and adds to the scope of market growth for osteoporosis drugs in Egypt.

The two fastest-growing age groups in the country are the elderly (65+) and the near-elderly (60-64), whose numbers will increase by 2.8 and 2.3 times, respectively, by 2050, relative to what they are in 2020 and this is the age bracket most affected by Osteoporosis. High Sunlight keeps people inside and this again increases demand for treatment of bone-related disorders.

However, osteoporosis is not a national health priority in Egypt and even though guidelines have been developed, it is not endorsed by the government of the country. There is absolutely no reimbursement policy for therapy and treatments due to which people must pay. These factors bring resistance to the market growth for the disease.

To Know More About COVID-19 Impact On Egypt Osteoporosis Drug Market @ https://www.prudentmarkets.com/sample-request/141597/

By Drug class

The market for the treatment of osteoporosis has been segmented into Bisphosphonates, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator, Strontium Ranelate, Calcitonin, PTH Analog, Rank Ligand Inhibitor

By Route of Administration

By route of administration, the drug market can be segmented into oral and injectables.

By Distribution Channel

By distribution channel, the osteoporosis drug market can be segmented into hospital pharmacies, online pharmacies, and retail pharmacies

Major Players

Egypt's Osteoporosis drug market appears to be fragmented and with the presence of several local and global companies including Novartis, GSK, Sanofi, MSD, Pharco, Amoun, EIPICO, Eva Pharma, Pfizer, Hikma. These companies occupied the largest share in Egypt's pharmaceutical market as of 2019.

Merck Sharp & Dohme (MSD Egypt) is established in Egypt as a Scientific Office in 1960. From 1960 until 1984, MSD products have either been imported through a public sector distribution company (EGYDRUG) or locally manufactured through a government-owned manufacturer (Al-Kahira Company) and a private sector company (EIPICO). It reached several milestones in the Egyptian market including Alendronate, the 1st non-hormonal therapy for osteoporosis with proven fracture reduction.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141597/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Egypt Osteoporosis Drug Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Egypt Osteoporosis Drug Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Egypt Osteoporosis Drug market
Chapter 2: Exclusive Summary - the basic information of the Egypt Osteoporosis Drug Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Egypt Osteoporosis Drug
Chapter 4: Presenting the Egypt Osteoporosis Drug Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Egypt Osteoporosis Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/141597/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Egypt Osteoporosis Drug Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.